MD introduces FLIPRTETRA Screening System with simultaneous 1536 liquid transfer
Sunnyvale, Calif., June 1, 2004 - Molecular Devices Corporation (Nasdaq: MDCC), today announced the introduction of FLIPRTETRA the first system that enables researchers to significantly increase throughput of cell-based assays by measuring 1536 kinetic measurements simultaneously.
The FLIPRTETRA, which debuts today at Molecular Devices' Drug Discovery Conference in Berkeley, California, is the only microplate detection system that simultaneously transfers liquid to 1536-well microplates, significantly reducing screening time and reagent consumption. This entirely new, modular system also offers traditional 96- and 384-well fluidics, easily convertible by the user within minutes, providing a seamless transition between higher-volume assays to those that require sub-microliter volume additions. FLIPRTETRA is also the first FLIPR® system to offer an expanded set of excitation wavelengths, significantly broadening its use beyond traditional calcium mobilization and membrane potential assays.
"FLIPR is the most widely-used screening system for GPCR analysis," stated Michael L. Biros, Marketing Director for Drug Discovery Instruments at Molecular Devices."With FLIPR Tetra, researchers can now increase the throughput and reduce the cost of their calcium mobilization and membrane potential assays even more-screening over 3,000 kinetic assays every six minutes using a few thousand cells per assay."
Commenting on the launch of the FLIPRTETRA, Stephen J. Oldfield, Ph.D., Molecular Devices" Vice President of Worldwide Marketing, stated, "Development of FLIPRTETRA was guided by senior-level drug discovery managers striving to reduce facilities and screening costs, as well as thousands of FLIPR users looking to improve ease-of-use and robustness. Oldfield further noted, "The FLIPRTETRA brings the multi-wavelength capability that our FlexStation® users have enjoyed to a high-throughput platform, paving the way for multi-wavelength applications. This new instrument platform also extends the user base for our growing family of reagent kits, including Calcium 3 and membrane potential kits."